End-of-day quote
Korea S.E.
18:00:00 2024-06-03 EDT
|
5-day change
|
1st Jan Change
|
3,890
KRW
|
0.00%
|
|
-0.51%
|
-12.98%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
316,639
|
256,100
|
330,635
|
205,154
|
141,464
|
143,064
|
Enterprise Value (EV)
1 |
344,459
|
292,037
|
352,787
|
228,295
|
151,265
|
156,080
|
P/E ratio
|
-30.8
x
|
5.97
x
|
-36.2
x
|
-17.3
x
|
14.8
x
|
5.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.7
x
|
1.85
x
|
2.31
x
|
1.23
x
|
0.73
x
|
0.65
x
|
EV / Revenue
|
2.93
x
|
2.11
x
|
2.47
x
|
1.37
x
|
0.78
x
|
0.7
x
|
EV / EBITDA
|
-243
x
|
38.9
x
|
-125
x
|
-95.7
x
|
9.78
x
|
8.82
x
|
EV / FCF
|
-30.5
x
|
-33
x
|
30.7
x
|
36.4
x
|
77.3
x
|
40.4
x
|
FCF Yield
|
-3.28%
|
-3.03%
|
3.26%
|
2.75%
|
1.29%
|
2.47%
|
Price to Book
|
3.91
x
|
1.89
x
|
0.88
x
|
0.92
x
|
0.99
x
|
1.05
x
|
Nbr of stocks (in thousands)
|
30,446
|
30,561
|
31,945
|
32,005
|
32,005
|
32,005
|
Reference price
2 |
10,400
|
8,380
|
10,350
|
6,410
|
4,420
|
4,470
|
Announcement Date
|
3/19/19
|
3/18/20
|
3/23/21
|
3/23/22
|
3/21/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
117,475
|
138,083
|
143,023
|
166,567
|
193,379
|
221,725
|
EBITDA
1 |
-1,415
|
7,516
|
-2,812
|
-2,387
|
15,469
|
17,693
|
EBIT
1 |
-4,529
|
3,396
|
-7,467
|
-7,427
|
10,377
|
11,849
|
Operating Margin
|
-3.86%
|
2.46%
|
-5.22%
|
-4.46%
|
5.37%
|
5.34%
|
Earnings before Tax (EBT)
1 |
-8,847
|
56,001
|
-8,340
|
-12,676
|
12,379
|
33,023
|
Net income
1 |
-10,218
|
43,646
|
-8,968
|
-11,854
|
9,561
|
26,211
|
Net margin
|
-8.7%
|
31.61%
|
-6.27%
|
-7.12%
|
4.94%
|
11.82%
|
EPS
2 |
-337.3
|
1,404
|
-285.6
|
-371.0
|
298.7
|
819.0
|
Free Cash Flow
1 |
-11,289
|
-8,839
|
11,489
|
6,272
|
1,958
|
3,863
|
FCF margin
|
-9.61%
|
-6.4%
|
8.03%
|
3.77%
|
1.01%
|
1.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
12.66%
|
21.83%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
20.48%
|
14.74%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/19
|
3/18/20
|
3/23/21
|
3/23/22
|
3/21/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
27,820
|
35,937
|
22,152
|
23,141
|
9,801
|
13,016
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-19.66
x
|
4.781
x
|
-7.878
x
|
-9.696
x
|
0.6336
x
|
0.7357
x
|
Free Cash Flow
1 |
-11,289
|
-8,839
|
11,489
|
6,272
|
1,958
|
3,863
|
ROE (net income / shareholders' equity)
|
-10.9%
|
37.4%
|
-3.43%
|
-3.68%
|
5.59%
|
19.3%
|
ROA (Net income/ Total Assets)
|
-1.77%
|
1.02%
|
-1.2%
|
-1.05%
|
2.17%
|
3.02%
|
Assets
1 |
577,757
|
4,278,988
|
745,996
|
1,129,923
|
439,788
|
866,637
|
Book Value Per Share
2 |
2,658
|
4,446
|
11,711
|
6,958
|
4,487
|
4,240
|
Cash Flow per Share
2 |
487.0
|
324.0
|
448.0
|
381.0
|
572.0
|
679.0
|
Capex
1 |
4,034
|
4,636
|
3,012
|
2,749
|
4,193
|
4,797
|
Capex / Sales
|
3.43%
|
3.36%
|
2.11%
|
1.65%
|
2.17%
|
2.16%
|
Announcement Date
|
3/19/19
|
3/18/20
|
3/23/21
|
3/23/22
|
3/21/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -12.98% | 90.77M | | +42.83% | 748B | | +34.11% | 598B | | -5.70% | 356B | | +18.06% | 325B | | +4.63% | 283B | | +17.02% | 245B | | +9.26% | 211B | | -4.21% | 209B | | +2.43% | 166B |
Other Pharmaceuticals
|